(TCAD) A Phase 2 multi-center, randomized, double blind, placebo controlled, parallel group study to evaluate the efficacy and safety of T-817MA in patients with mild to moderate Alzheimer’s Disease

The PI of this project was:

This project was funded by:

The term of this project was: August 2014 to April 2016

The number of subjects scanned during this project was: 12